initial public offerings (IPOs) trading on American exchanges

Thursday, March 6, 2014

Ophthotech (OPHT) began trading on the NASDAQ on 25 September 2013


Ophthotech Corporation is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye. The Company’s advanced product candidate is Fovista, which the Company is developing for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is a serious disease of the central portion of the retina, known as the macula, which is responsible for detailed central vision and color perception. It is characterized by abnormal new blood vessel formation and growth, referred to as neovascularization, which results in blood vessel leakage, retinal distortion and scar formation. If untreated, the progressive retinal damage results in rapid, irreversible and severe vision loss. Wet AMD is the cause of blindness in patients over the age of 55 in the United States and the European Union.


35th Floor One Penn Plaza
NEW YORK, NY 10119
United States

Key stats and ratios

Q4 (Dec '13)2013
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets--
Return on average equity--

No comments:

Post a Comment